Back
Textron, Inc. 10K Form
Buy
62
TXT
Textron, Inc.
Last Price:
$83.12
Seasonality Move:
4.43%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-25 | 10Q | TXT/Textron, Inc. Quarterly |
| 2024-02-12 | 10K | TXT/Textron, Inc. Annual |
| 2023-10-26 | 10Q | TXT/Textron, Inc. Quarterly |
| 2023-07-27 | 10Q | TXT/Textron, Inc. Quarterly |
| 2023-04-27 | 10Q | TXT/Textron, Inc. Quarterly |
| 2023-02-16 | 10K | TXT/Textron, Inc. Annual |
Receive TXT News And Ratings
See the #1 stock for the next 7 days that we like better than TXT
TXT Financial Statistics
Sales & Book Value
| Annual Sales: | $13.7B |
|---|---|
| Cash Flow: | $273M |
| Price / Cash Flow: | 21.93 |
| Annual Sales: | $42.54 |
| Price / Book: | 1.97 |
Profitability
| EPS (TTM): | 4.54590 |
|---|---|
| Net Income (TTM): | $828M |
| Gross Margin: | $2.5B |
| Return on Equity: | 11.39% |
| Return on Assets: | 4.89% |
Textron, Inc. Earnings Forecast
Key Textron, Inc. Financial Ratios
-
The Gross Profit Margin over the past 45 years for TXT is 18.26%.
-
The Selling, General & Administrative Expenses for TXT have been equal to 8.44% of Gross Profit Margin.
-
The Research & Development expenses have been 3.58% of Revenue.
-
The Interest Expense is 11.76% of Operating Income.
-
The Net Earning history of TXT is 6.02% of Total Revenues.
-
Per Share Earnings over the last 45 years have been positive in 28 years.
Textron, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Aerospace & Defense |
| Sector: | Industrials |
| Current Symbol: | TXT |
| CUSIP: | 883203 |
| Website: | textron.com |
Debt
| Debt-to-Equity Ratio: | 0.55 |
|---|---|
| Current Ratio: | 1.71 |
| Quick Ratio: | 0.57 |
Price-to-Earnings
| Trailing P/E Ratio: | 19.33 |
|---|---|
| Forward P/E Ratio: | 12.21 |
TXT Technical Analysis vs Fundamental Analysis
Buy
62
Textron, Inc. (TXT)
is a Buy
Is Textron, Inc. a Buy or a Sell?
-
Textron, Inc. stock is rated a BuyThe current Textron, Inc. [TXT] share price is $83.14. The Score for TXT is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.